Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Adamas Pharmaceuticals Inc (ADMS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Summary

Adamas Pharmaceuticals Inc (Adamas) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The companys pipeline products include ADS-5102, which is used for the treatment of CNS-related conditions including levodopa-induced dyskinesia in Parkinsons disease patients; and major symptoms associated with multiple sclerosis in patients with walking impairment. Adamas product portfolio also includes namzaric and namenda XR. Its products are also used in the treatment of traumatic brain injury. The company serves in different parts of the US. Adamas is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc (ADMS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

TABLE OF CONTENTS

2
List of Tables 4
List of Figures 5
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 11
Equity Offering 12
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 12
Adamas Pharma Raises USD66 Million in Public Offering of Shares 13
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 14
Adamas Pharma Completes IPO For US$48 Million 15
Debt Offering 16
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 16
Adamas Pharmaceuticals Inc - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Strategy And Business Planning 21
Jan 12, 2016: Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones 21
Financial Announcements 22
May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 22
Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 23
Nov 03, 2016: Adamas Reports Third Quarter 2016 Financial Results 25
Aug 04, 2016: Adamas Reports Second Quarter 2016 Financial Results 27
May 10, 2016: Adamas Reports First Quarter 2016 Financial Results 28
Feb 23, 2016: Adamas Reports Fourth Quarter and Full Year 2015 Financial Results 29
Corporate Communications 30
Jun 28, 2017: Adamas Appoints New Chief Financial Officer 30
Sep 22, 2016: Adamas Appoints Michael F. Bigham to Board of Directors 31
Product News 32
Jul 19, 2016: Allergan and Adamas Announce New Expanded Indication for NAMZARIC (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimers Disease 32
Apr 27, 2017: Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 33
Jan 08, 2017: Adamas Pharma Outlines Key Business Priorities for 2017, Provides Update on ADS-5102 34
Jan 08, 2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101 35
Product Approvals 36
Jan 06, 2017: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinsons Disease 36
Oct 27, 2016: Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinsons Disease 37
Clinical Trials 38
May 22, 2017: Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 38
Apr 24, 2017: Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinsons Disease 40
Apr 18, 2017: Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting 42
Mar 28, 2017: Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting 43
Feb 28, 2017: Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinsons Disease and Movement Disorders Congress 44
Feb 17, 2017: Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 45
Jan 03, 2017: Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy 46
Sep 20, 2016: Adamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson Disease Patients at the 4th World Parkinson Congress 47
Sep 12, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress 49
Jun 22, 2016: Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinsons Disease and Movement Disorders 50
Jun 13, 2016: Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis Patients 52
May 16, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia at the 20th International Congress of Parkinsons and Movement Disorders 53
Apr 28, 2016: Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinsons Disease 54
Apr 19, 2016: Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated with Parkinsons Disease at the American Academy of Neurology Annual Meeting 56
Apr 14, 2016: Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List Of Tables

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adamas Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 11
Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 12
Adamas Pharma Raises USD66 Million in Public Offering of Shares 13
Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 14
Adamas Pharma Completes IPO For US$48 Million 15
Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 16
Adamas Pharmaceuticals Inc, Key Competitors 18
Adamas Pharmaceuticals Inc, Key Employees 19

List Of Figures

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Adamas Pharmaceuticals Inc (ADMS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review

Rocket Pharmaceuticals Inc (RCKT) - Financial and Strategic SWOT Analysis Review

Sunesis Pharmaceuticals Inc (VIRX) - Financial and Strategic SWOT Analysis Review

FAQs